Mar-04-21 Resumed
Guggenheim
Buy
Mar-01-21 Upgrade
Evercore ISI
In-line → Outperform
$90 → $100
Aug-20-20 Downgrade
William Blair
Outperform → Mkt Perform
Aug-20-20 Downgrade
Citigroup
Buy → Neutral
$148 → $86
Aug-19-20 Downgrade
Stifel
Buy → Hold
$127 → $100
Aug-19-20 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
Aug-19-20 Downgrade
Evercore ISI
Outperform → In-line
Jul-08-20 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$125
Jul-06-20 Reiterated
Citigroup
Buy
$105 → $148
Jan-28-20 Initiated
BMO Capital Markets
Market Perform
Jan-27-20 Initiated
BMO Capital Markets
Market Perform
Jan-24-20 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$111 → $113
Nov-27-19 Upgrade
Barclays
Equal Weight → Overweight
$86 → $98
Nov-12-19 Initiated
SunTrust
Buy
$110
Oct-17-19 Resumed
BofA/Merrill
Buy
$90
May-23-19 Resumed
Citigroup
Buy
Apr-09-19 Resumed
Raymond James
Outperform
Jan-02-19 Downgrade
Raymond James
Outperform → Mkt Perform
Dec-14-18 Initiated
Wolfe Research
Outperform
Oct-01-18 Initiated
Cantor Fitzgerald
Overweight
$126
Mar-03-21 08:31AM
Feb-26-21 10:50PM
12:02PM
09:16AM
Feb-25-21 02:30PM
Feb-24-21 10:09AM
08:30AM
Feb-18-21 04:01PM
Feb-11-21 11:40AM
Feb-06-21 01:52AM
Jan-28-21 09:00AM
Jan-26-21 11:40AM
08:30AM
Jan-22-21 07:55AM
Jan-15-21 10:50PM
Jan-12-21 09:24AM
Jan-11-21 10:58AM
10:14AM
08:37AM
08:11AM
Jan-10-21 06:44PM
Jan-07-21 11:40AM
Jan-05-21 08:30AM
Jan-04-21 08:42AM
Dec-31-20 09:24AM
Dec-21-20 08:29AM
Dec-18-20 12:14PM
Dec-17-20 04:21PM
09:42AM
Dec-14-20 01:38PM
Dec-09-20 04:02PM
Dec-05-20 11:32AM
Dec-01-20 08:30AM
Nov-24-20 03:35PM
03:00PM
11:39AM
10:15AM
10:00AM
09:53AM
09:13AM
06:20AM
Nov-23-20 10:50PM
05:40PM
04:10PM
01:27PM
12:00PM
12:00PM
11:00AM
11:00AM
10:15AM
09:39AM
06:32AM
Nov-22-20 10:50PM
01:00PM
Nov-21-20 07:00AM
Nov-20-20 10:50PM
07:50PM
07:09PM
01:00PM
01:00PM
11:30AM
11:20AM
11:00AM
09:33AM
08:00AM
Nov-19-20 06:09PM
04:40PM
04:37PM Investor's Business Daily
01:57PM
12:30PM
12:15PM
11:08AM
11:00AM
10:30AM
09:49AM
06:20AM
Nov-18-20 11:18PM
10:50PM
03:28PM
02:00PM
11:30AM
11:00AM
06:20AM
Nov-17-20 10:50PM
02:58PM
01:30PM
12:30PM
11:45AM
11:00AM
08:29AM
06:20AM
Nov-16-20 10:50PM
03:35PM
02:45PM
12:00PM
11:08AM
11:00AM
06:20AM
02:15AM
Nov-15-20 11:00AM
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIENAIME JEAN JACQUES Chief Executive Officer Feb 19 Option Exercise 26.49 7,000 185,430 302,552 Feb 22 08:38 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 19 Sale 83.58 7,000 585,060 295,552 Feb 22 08:38 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 18 Option Exercise 26.49 7,000 185,430 302,552 Feb 19 09:22 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 18 Sale 85.08 7,000 595,560 295,552 Feb 19 09:22 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 17 Option Exercise 26.49 8,000 211,920 303,552 Feb 18 09:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 17 Sale 84.54 8,000 676,320 295,552 Feb 18 09:45 PM LAWLIS V BRYAN Director Feb 16 Option Exercise 26.49 7,500 198,675 26,350 Feb 18 06:43 PM LAWLIS V BRYAN Director Feb 16 Sale 87.41 7,500 655,575 18,850 Feb 18 06:43 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 29 Option Exercise 26.49 8,334 220,768 303,886 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 29 Sale 82.67 8,334 688,972 295,552 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 28 Option Exercise 26.49 8,333 220,741 303,885 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 28 Sale 82.91 8,333 690,889 295,552 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 27 Option Exercise 26.49 8,333 220,741 303,885 Jan 28 07:35 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 27 Sale 85.49 8,333 712,388 295,552 Jan 28 07:35 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 29 Sale 88.18 1,500 132,270 295,552 Dec 30 08:02 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 28 Sale 88.77 1,500 133,155 297,052 Dec 30 08:02 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Oct 14 Sale 79.91 2,121 169,489 61,281 Oct 15 07:17 PM HERON ELAINE J Director Oct 07 Option Exercise 26.49 15,000 397,350 66,968 Oct 08 08:35 PM PYOTT DAVID E I Director Aug 31 Buy 78.26 12,800 1,001,715 30,740 Sep 01 09:44 PM GREY MICHAEL G Director Aug 03 Option Exercise 26.49 2,500 66,225 45,340 Aug 05 06:56 PM GREY MICHAEL G Director Aug 03 Sale 120.35 2,500 300,875 42,840 Aug 05 06:56 PM FUCHS HENRY J President, Worldwide R&D Jul 20 Option Exercise 65.97 126,389 8,337,656 229,384 Jul 22 05:32 PM FUCHS HENRY J President, Worldwide R&D Jul 20 Sale 130.00 126,389 16,430,570 102,995 Jul 22 05:32 PM FUCHS HENRY J President, Worldwide R&D Jul 13 Option Exercise 65.97 23,011 1,518,094 126,006 Jul 15 09:32 PM FUCHS HENRY J President, Worldwide R&D Jul 13 Sale 130.00 23,011 2,991,430 102,995 Jul 15 09:32 PM Dere Willard H Director Jun 26 Sale 123.61 4,430 547,592 13,290 Jun 30 02:11 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Jun 19 Option Exercise 63.10 15,000 946,500 78,402 Jun 23 07:24 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Jun 19 Sale 124.00 15,000 1,860,000 63,402 Jun 23 07:24 PM LAWLIS V BRYAN Director Jun 05 Sale 107.46 4,430 476,048 18,850 Jun 09 06:04 PM BIENAIME JEAN JACQUES Chief Executive Officer May 08 Option Exercise 21.51 20,000 430,200 318,552 May 12 01:51 PM BIENAIME JEAN JACQUES Chief Executive Officer May 08 Sale 91.72 20,000 1,834,400 298,552 May 12 01:51 PM BIENAIME JEAN JACQUES Chief Executive Officer May 04 Option Exercise 21.51 5,000 107,550 303,552 May 05 07:22 PM BIENAIME JEAN JACQUES Chief Executive Officer May 04 Sale 88.00 5,000 440,000 298,552 May 05 07:22 PM BIENAIME JEAN JACQUES Chief Executive Officer May 01 Option Exercise 21.51 4,000 86,040 302,552 May 05 07:22 PM Davis George Eric EVP, General Counsel May 01 Sale 89.38 12,504 1,117,608 65,677 May 04 09:45 PM BIENAIME JEAN JACQUES Chief Executive Officer May 01 Sale 89.38 4,000 357,520 298,552 May 05 07:22 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 28 Option Exercise 21.51 20,000 430,200 318,213 Apr 29 07:40 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 28 Sale 97.58 20,000 1,951,600 298,213 Apr 29 07:40 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 27 Option Exercise 21.51 20,000 430,200 318,213 Apr 29 07:40 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 27 Sale 97.73 20,000 1,954,600 298,213 Apr 29 07:40 PM FUCHS HENRY J President, Worldwide R&D Apr 24 Sale 95.88 20,000 1,917,617 102,656 Apr 28 02:37 PM FUCHS HENRY J President, Worldwide R&D Apr 20 Sale 90.00 17,213 1,549,170 122,656 Apr 22 05:15 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 09 Option Exercise 21.51 10,000 215,100 308,213 Apr 13 06:24 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 09 Sale 79.06 10,000 790,600 298,213 Apr 13 06:24 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Apr 08 Sale 79.98 2,407 192,512 63,064 Apr 09 07:58 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 07 Option Exercise 26.49 1,000 26,490 298,213 Apr 08 08:54 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Apr 01 Sale 82.00 1,537 126,034 65,471 Apr 02 08:39 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 25 Sale 78.47 1,618 126,964 67,008 Mar 26 08:34 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 24 Sale 74.36 2,041 151,769 68,626 Mar 26 08:34 PM LAWLIS V BRYAN Director Mar 17 Option Exercise 21.51 3,750 80,662 22,730 Mar 18 08:46 PM LAWLIS V BRYAN Director Mar 17 Sale 75.39 3,750 282,712 18,980 Mar 18 08:46 PM LAWLIS V BRYAN Director Mar 16 Sale 76.52 4,610 352,757 18,980 Mar 18 08:46 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 09 Option Exercise 21.51 10,000 215,100 306,443 Mar 11 09:01 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 09 Sale 89.52 10,000 895,200 296,443 Mar 11 09:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite